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Islet transplantation is a promising therapy for patients with type 1 diabetes that can provide moment-to-moment metabolic
control of glucose and allow them to achieve insulin independence. However, two major problems need to be overcome: (1)
detrimental immune responses, including inﬂammation induced by the islet isolation/transplantation procedure, recurrence
autoimmunity, and allorejection, can cause graft loss and (2) inadequate numbers of organ donors. Several gene therapy
approaches and pharmaceutical treatments have been demonstrated to prolong the survival of pancreatic islet grafts in animal
models; however, the clinical applications need to be investigated further. In addition, for an alternative source of pancreatic β-cell
replacement therapy, the ex vivo generation of insulin-secreting cells from diverse origins of stem/progenitor cells has become an
attractive option in regenerative medicine. This paper focuses on the genetic manipulation of islets during transplantation therapy
and summarizes current strategies to obtain functional insulin-secreting cells from stem/progenitor cells.
1.Introduction
Type 1 diabetes (T1D) is an autoimmune disease charac-
terized by the progressive destruction of insulin-producing
cells in the pancreatic islets by autoreactive T cells, which
eventually leads to hyperglycemia. The disease accounts for
about 10% of all cases of diabetes, occurs most commonly
in people of European descent, and aﬀects two million
people in Europe and North America [1]. There is a marked
geographic variation in the incidence, probably because the
diﬀerent populations vary in genetic susceptibility/resistance
factors or in exposure to environmental triggers. For
instance, a child in Finland (Northern Europe) is about 80
times more likely to acquire the disease than a child in China
(Eastern Asia) [2]. The current global increase in incidence
of 3% per year is well established [3, 4], and this rapid rise
stronglysuggeststhatenvironmentalfactorsshouldbeacting
on susceptibility genes and contributing to the evolving
epidemiology of T1D.
InpatientswithT1D,dailydeliveryofinsulinbyinjection
or a pump is crucial for metabolic control. However, this
exogenous insulin delivery cannot achieve physiological
control of blood glucose concentrations and also has the risk
of causing hypoglycemic episodes. Moreover, a signiﬁcant
proportion of patients suﬀerschronic and degenerative com-
plications, such as nephropathy, retinopathy, and vascular
andheartdisease[5,6].Theappropriatetreatmenttoachieve
insulin independence for T1D is replacement of the β-cell
mass, currently being accomplished through whole pancreas
transplantation and islet transplantation. Transplantation
of the whole pancreas is a standard treatment for diabetic
patients, which can achieve insulin independence with a sin-
gle donor [7]. Pancreatic islet transplantation is a safer and
less invasive method than whole-organ transplant therapy,
which causes thrombosis, pancreatitis, and peritonitis. How-
ever, the major drawback of islet transplantation compared
with pancreas transplantation is the greater requirement for
donors and the lower 5-year insulin independence rate [8].2 International Journal of Endocrinology
Transplantation therapy should provide a better quality
of life than current therapies and should help avoid compli-
cations. Unfortunately, immune-mediated destruction and
inadequate numbers of donor organs for transplantation are
the major obstacles to achieving insulin independence and
long-term survival of grafts in this therapy. To circumvent
those problems, genetically modifying islets to enhance their
resistance to immune attack and explorations of alternative
sources of insulin-secreting cells are being investigated
intensively. In this paper, we will summarize the current
knowledge regarding immunomodulatory therapy in islet
transplantation and examine alternative sources of insulin-
secreting cells for cell replacement therapy.
2.MechanismsInvolvedinIsletGraft
Rejection: Nonspeciﬁc Inﬂammation andthe
Contribution of T-Helper-Cell Subsets
The process of islet isolation also triggers a cascade of stress-
ful events in the cells involving the induction of apoptosis
or necrosis and production of proinﬂammatory molecules
that negatively inﬂuence islet viability and function. Trans-
plantation procedures such as collagenase-based islet iso-
lation trigger proinﬂammatory cytokine and chemokine
production by the islets. Proinﬂammatory cytokines such as
interleukin- (IL-) 1β and tumor necrosis factor- (TNF-) α
produced by islet-resident macrophages are toxic to islets
and can induce the local production of reactive oxygen
species (ROS) [9, 10]. By contrast, chemokine receptors such
as chemokine (C-C motif) receptor (CCR)2, CCR5, and
C-X-C chemokine receptor (CXCR)3, and their ligands are
crucial to generate acute islet allograft rejection [11]. Taken
together, the inﬂammatory cytokines, chemokines, and ROS
contribute to the ﬁrst line of attack to the islets, which can
cause apoptosis and loss of function.
The second barrier against successful transplantation is
recipient alloimmunity and autoimmunity. Previous reports
have demonstrated that Th1 cells, type 1 cytotoxic CD8+
T cells, and Th1-type cytokines such as interferon (IFN)-γ
and IL-2 are commonly associated with graft rejection [12–
15]. Th1 responses initiate allograft rejection by promoting
cytotoxic T-cell activities and IFN-γ-mediated delayed-type
hypersensitivity reactions, whereas Th2 responses cause
allograft damage through the recruitment of eosinophils
induced by IL-4 and IL-5. Moreover, cytokines produced by
non-T-cell sources from the graft microenvironment, such
as IL-7 produced by stromal cells and IL-15 produced by
activated macrophages and endothelial cells, further support
the idea of alloreactive T-cell proliferation [14, 16].
Recently, the role of subsets of Th cells in graft rejection
has been reexamined after the identiﬁcation and thorough
characterization of Th17 cells. Several lines of evidence
have demonstrated that Th17 cells have the capacity to
cause rejection of cardiac allografts [17–19]. However, it is
not clear whether Th1 and Th17 cells work synergistically
or sequentially to cause graft rejection. In our laboratory,
we have investigated the relative contribution of Th1 and
Th17 cells in the autoimmune-mediated rejection of islets
in a nonobese diabetic (NOD) mouse model. We have
demonstrated that Th1 cells play a crucial role in the
destruction of the islet graft, whereas Th17 cells constitute
a much smaller population in the islet graft and might play
only a minor destructive role in this model of autoimmune
islet transplantation (Chou et al., manuscript in revision).
In summary, understanding the inﬂammatory factors
thatattackisletsduringtheearlyphaseanddissectingtherole
of the eﬀector T-cell subsets in the rejection responses might
contribute to developing target therapies to protect islets
from inﬂammatory insults and to modulate T-cell responses.
3.Strategies to ProtectIslets from
Inﬂammatory Insultsand
T-Cell-MediatedImmunity
In autoimmune diabetes, pancreatic β cells suﬀer from
inﬂammatory stress following T-cell-mediated destruction.
Macrophages and/or dendritic cells in the islet microen-
vironment produce proinﬂammatory cytokines and free
radicals, which induce β-cell damage. Activated T cells
express death receptors and release cytotoxic molecules
including granzyme B, perforin, or cytokines to further
activate other immune cells and exacerbate β-cell death.
Several preventive and therapeutic approaches have been
demonstrated to protect β cells from immune attack,
including the modulation of T-cell activity and inhibition of
inﬂammatory responses in the islet microenvironment. To
protect islets from immune attack, many gene targets that
exhibit strong immunoregulatory eﬀects and antiapoptotic
eﬀects have been introduced to the islets through diﬀerent
approaches:generationoftransgenicmiceusingislet-speciﬁc
promoters to carry genes of interest, delivery of genes into
islets by viral vectors or transfection, and the administration
of recombinant proteins and drugs.
4. Transgenic Overexpression of
Regulatory GenesinIslets
Genetically manipulating islets by transgenic techniques was
originally designed for study of the immunopathogenesis
of autoimmune diabetes. This could help in dissecting the
roles of diﬀerent cytokines, death receptors, and major his-
tocompatibility complex (MHC)/costimulation molecules in
β-cell destruction (reviewed in [20]). Among the transgenic-
mouse models that have been generated, some molecules
display strong immunoregulatory functions and cytopro-
tective eﬀects, which could be applied further in islet
transplantation therapy (Table 1).
4.1. Cytokines and Cytokine Signaling. It is well established
that proinﬂammatory cytokines and Th1-type cytokines
are toxic to islets whereas IL-4 and transforming growth
factor- (TGF-) β a r ep o s t u l a t e dt ob ep r o t e c t i v e .T r a n s g e n i c
expression of IL-4 in β cells under the control of the
insulin promoter in NOD mice suppresses insulitis and
diabetes; however, islet expression of IL-4 is incapable of
preventing islet rejection in diabetic recipients [21]. In otherInternational Journal of Endocrinology 3
Table 1: Transgenic overexpression of regulatory genes in the islets and their eﬀects on islet transplantation.
Promoter Gene of
interest Animal strain Diabetic incidence Eﬀect on islets Eﬀects on islet transplantation Reference
Human
insulin IL-4 NOD Decreased Protect islets from
autoimmune destruction No signiﬁcant protective eﬀect [21]
Rat insulin TGF-β NOD Decreased Small clusters of micro-islet
N, and no protective eﬀect
when use pancreata in an
allogeneic transplantation
model
[22, 23]
Glucagon TGF-β NOD Decreased
Morphologically normal,
no other phenotypes
mentioned
N[ 24]
Rat insulin TNF-α NOD Decreased Massive insulitis N [25]
Human
insulin SOCS1 B6
B6 is not a
diabetes-prone
mouse strain
Not mentioned
Expression of SOCS-1 in islets
delays allografts rejection (B6
to Balb/c) but cannot
circumvent destruction of the
islets by the recurrence of the
tissue-speciﬁc autoimmune
process of spontaneous
diabetes (B6 to diabetic NOD)
[26]
Human
insulin PD-L1 NOD Decreased Protect from autoimmune
destruction No signiﬁcant protective eﬀect [27]
Glial
ﬁbrillary
acidic protein
PD-L1 NOD Increased Enhance the severity of
insulitis N[ 28]
Rat insulin PD-L1 B6
Induces
T-cell-mediated
spontaneous
diabetes in B6
mouse
Induce insulitis Accelerate allograft rejection [29]
Human
insulin
Single chain
anti-CTLA-4
Fv
NOD Decreased Protect islets from
autoimmune destruction
Prolong islet grafts survival in
diabetic NOD mice [30]
Rat insulin CTLA-4-Ig B6
B6 is not a
diabetes-prone
mouse strain
Morphologically normal
N, and transplantation of
CTLA4-Ig transgenic
pancreata combine with
transient systemic CD4 T cell
depletion in recipients
enhance allograft acceptance
[31]
Human
insulin Thioredoxin NOD Decreased
Do not attenuate the
development of insulitis N[ 32]
Human
insulin
Heme
oxygenase 1 NOD Decreased
Protect islets from
autoimmune destruction
Resistant to inﬂammatory
cytokine-induced apoptosis
Prolong islet grafts survival in
diabetic NOD mice [33]
Human
insulin DcR3 NOD Decreased Protect islets from
autoimmune destruction
Increase the successful rate of
implantation and prolong islet
grafts survival in diabetic
NOD mice
[34]
Human
insulin D6 NOD Decreased Protect islets from
autoimmune destruction N[ 35]
NOD: Nonobese diabetic mouse, a spontaneous autoimmune diabetes mouse strain; SOCS-1: suppressor of cytokine signaling-1; PD-L1: programmed death
1 ligand 1; CTLA-4: cytotoxic T lymphocyte antigen 4; DcR3: decoy receptor 3; D6: an inﬂammatory CC chemokine decoy receptor; N: not tested.4 International Journal of Endocrinology
studies, expression of TGF-β driven by an insulin promoter
[22] or a glucagon promoter [24] protected islets from
autoimmune destruction in NOD mice. However, the β-
cell-speciﬁc expression of TGF-β changes the pancreatic
architecture [22], and this TGF-β-expressing pancreatic
tissue fails to inhibit allograft rejection [23]. In other aspects,
the inhibition of toxic cytokine signaling in islets represents
an attractive strategy in designing therapies to prevent islet
destruction. Islets with transgenic expression of suppressor
of cytokine signaling 1 (SOCS1) show delayed allograft
rejection but cannot circumvent destruction of the islets by
the autoimmune destruction [26].
4.2. Negative Costimulation Engagement. T-cell activation
occurs through two important signals: one is the T-cell
receptor recognizing a speciﬁc peptide MHC complex and
the other is a costimulatory signal. Upon the T-cell activa-
tion, the expression of negative costimulatory molecules is
induced. The programmed death (PD)-1 and cytotoxic T-
lymphocyte antigen (CTLA)-4 are two important negative
costimulatory molecules expressed on T cells, which control
their eﬀector functions, tolerance, and autoimmunity [36].
We have demonstrated that transgenic expression of PD-
L 1( l i g a n do fP D - 1 )[ 27] or a membrane-bound, ago-
nistic single-chain anti-CTLA-4 Fv antibody (anti-CTLA-
4s c F v )[ 30] on islets in NOD mice reduces the severity
of insulitis and suppresses the development of diabetes.
In an islet transplantation study, transgenic anti-CTLA-4
scFv prolonged islet graft survival and reduced the Th1 cell
counts in islet grafts after transplantation into spontaneous
diabetic NOD mice. However, the expression of PD-L1
on islets could not prolong graft survival [27]. The role
of PD-L1 in the regulation of T-cell tolerance to islets
needs to be further investigated because the transgenic
expression of PD-L1 on islets in mice with a B6 background
induced T-cell-mediated spontaneous diabetes, and the islets
from transgenic mice displayed accelerated rejection in an
allogeneic transplantation model [29].
4.3. Anti-Inﬂammatory, Antiapoptotic, and Antioxidative
Molecules. Inﬂammatory cytokines such as IL-1β,T N F - α,
and IFN-γ sensitize β cells to Fas-dependent and/or other
death receptor-mediated apoptosis [37] and induce ROS
formation in β cells. Because islets produce very low levels
of antioxidative enzymes and are very sensitive to oxidative
stress [38], the reduction of ROS levels in islets is crucial for
maintaining the function and viability of islets. Others and
we have demonstrated that β-cell-speciﬁc expression of the
antiapoptotic and anti-inﬂammatory proteins, thioredoxin
(TRX) [32] or heme oxygenase-1 (HO-1) [33], prevented
autoimmune diabetes in NOD mice. Moreover, the islets
from HO-1 transgenic mice survived longer in diabetic
recipients, indicating that control of the initial inﬂammatory
responses can promote graft survival. The roles of ROS
scavengersinislettransplantationhavealsobeeninvestigated
in transgenic mouse models. Thus, several β-cell-speciﬁc
transgenic mice with diﬀerent antioxidant enzymes have
been generated (reviewed in [39]). In general, islets with
transgenic antioxidative genes (e.g., catalase, glutathione
peroxidase, metallothionein, copper/zinc superoxide dismu-
tase, and manganese superoxide dismutase) are resistant to
oxidative stress induced by chemicals [40–42]o rh y p o x i a
[43]; however, they are still sensitive to proinﬂammatory
cytokines induced cytotoxicity [41]. Among these transgenic
mice, islets from metallothionein transgenic mice showed
p r o l o n g e ds u r v i v a lo fi s l e tg r a f t si na na l l o g e n e i ct r a n s p l a n -
tation model [43].
In summary, most ex vivo studies have shown that over-
expression of antioxidative genes in islets protects them from
oxidative injury; however, the in vivo function and survival
of these genetically modiﬁed islets in diabetic recipients have
not produced overt success.
5.GeneticallyEngineeringIsletsby
Transfection or Transduction
The direct delivery of protective and therapeutic genes to
islet grafts can overcome many problems; for example, the
therapeutic agents cannot be targeted locally and might have
eﬀects on other organs or tissues, causing unexpected side
eﬀects. By using gene therapy, islets can be manipulated by
any vector system ex vivo without exposing the recipient
to the vectors. Moreover, graft-speciﬁc gene therapy can
provide prolonged, safe, and locally controlled gene expres-
sion. In this regard, ex vivo manipulation of islets by gene
transfer systems becomes an attractive approach to protect
grafts from immune attack. However, the gene delivery
systems applied should be considered carefully. In general,
nonimmunogenic vectors that cannot activate the host’s
immune response are used for long-term gene expression
[44].
Many strategies have been proven to improve the func-
tion of islet grafts and protect grafts from immune
attack (Table 2). These approaches include blockade of co-
stimulation signals by CTLA-4-Ig [45, 46]; downregulation
of Th1 responses by overexpression of galectin-9 (Chou et
al., manuscript in revision); overexpression of antiapoptotic
and antioxidative molecules such as B-cell lymphoma (Bcl)-
2[ 47], TRX [48], and superoxide dismutases (SODs) [49];
blockade of inﬂammatory cytokine signaling by overexpres-
sion of IL-1 receptor antagonist protein [50]; overexpression
of anti-inﬂammatory cytokines such as TGF-β [51], IL-10
[52], and IL-4 [53].
In summary, these strategies signiﬁcantly reduce apop-
tosis in islet grafts and prolong graft survival in diabetic
recipients. However, the application of these protective
genes to transplantation therapy has not been successful.
In general, therapeutic targets that have paracrine actions
would exert more marked biological eﬀects than membrane-
bound or intracellular molecules. Moreover, the eﬃciency
of gene delivery to islets and the expression levels of target
proteins in the microenvironment of grafts are closely linked
to the protective eﬀect in the grafts. Therefore, better results
might have been obtained by using a “cocktail” therapy, for
example, combining antiapoptotic and anti-inﬂammatory
genes, which could display synergistic protective eﬀects.International Journal of Endocrinology 5
Table 2: Genetically engineered islets for transplantation therapy.
Vector type Gene carried by vector Eﬀect on islet transplantation Reference
Magnetic iron oxide
nanoparticles siRNA to caspase 3 Decrease cell apoptosis in recipients [54]
Adenovirus X-linked inhibitor of
apoptosis protein (XIAP)
Increase successful rate of islet transplantation and reduce cell
apoptosis in a syngeneic model [55]
Gene gun transfection CTLA-4-Ig Prolong islet grafts’ survival in an allogeneic model [45]
Adenovirus/lentivirus CTLA-4-Ig or TGF-β Prolong islet grafts’ survival in a xenogenetic model (rat to
mouse) [46]
Transfection by Lipofectin Indoleamine 2,
3-dioxygenase (IDO) Prolong islet grafts’ survival in an allogeneic model [56]
Adenovirus TGF-β Prolong islet grafts’ survival in diabetic NOD mice [51]
Adeno-associated virus IL-10 Prolong islet grafts’ survival in diabetic NOD mice [52]
Adenovirus IL-10
Combine with cyclosporin A, prolong islet grafts survival in an
allogeneic model [57]
Adenovirus Bcl-2
Prolong islet grafts’ survival and maintain functional islet
mass in STZ-induced diabetic mice in a xenogenetic model
(nonhuman primate to mouse)
[47]
Adenovirus Manganese superoxide
dismutase (MnSOD)
Prolong islet grafts’ survival in STZ-induced diabetic
NOD/SCID mice after challenge with diabetogenic splenocytes [49]
Lentivirus Thioredoxin Prolong islet grafts’ survival in diabetic NOD mice [48]
Lentivirus Galectin-9 Prolong islet grafts’ survival in STZ-induced diabetic
NOD/SCID mice after challenge with diabetogenic splenocytes
Chou et al.,
manuscript in
preparation
6. AlternativeSources of Insulin-Producing
Cells: Cell Replacement Therapy
by Stem/Progenitor Cell-Derived
Insulin-ProducingCells
Although islet transplantation is seen as a “cure” therapy for
diabetes, this procedure is hampered by the limited number
of donors for isolating islets. Many alternative approaches
that can be applied to obtain insulin-secreting cells are being
investigated intensively [58]. These include the following: (1)
the production of surrogate cells by genetically modifying
nonendocrine cells to secrete insulin in response to glucose
challenge [59], (2) the transdiﬀerentiation of nonendocrine
stem/progenitor cells or mature cells to glucose-responsive
adult tissues [60, 61], (3) the regulated diﬀerentiation of islet
stem/progenitor cells to produce large numbers of mature,
functional islets [62, 63], (4) the in vitro diﬀerentiation of
stem cells to become insulin-secreting cells, and (5) the in
vitrodiﬀerentiationofinducedpluripotentstemcells(iPSCs)
derived from patients to form pancreatic β-like cells.
Stemcellscanreproducethemselves(self-renew)andcan
diﬀerentiate into many cell types. These features make them
an ideal focus for regenerative medicine. Besides, stem cells
havestrongimmunosuppressiveeﬀectsandcansecretemany
trophic factors that promote the regeneration of damaged
tissues.Thus,stemcellshavebecomeanattractivealternative
cell source to treat diabetes. There are many stem cell types
available as a potential source for the generation of insulin-
producingcells,includingembryonicstemcells(ESCs),adult
stem cells, and, most recently, the iPSCs.
Previous reports have demonstrated that ESCs can be
induced to become insulin-secreting tissue with structures
similar to pancreatic islets [64, 65], However, these cells
are often unresponsive to glucose or produce lower levels
of insulin compared with the endogenous β cells, which is
insuﬃcient to control normoglycemia in diabetic recipients
in a mouse model [64]. ESCs have not yet been used ther-
apeutically for treating diabetes mellitus in humans because
the animal experiments have not progressed suﬃciently to
justify this approach; for example, the positive insulin stain-
ing of ESC-derived pancreatic-like tissue probably occurs by
uptake of insulin from the culture medium [66], and the
intermediate stages involved in the diﬀerentiation pathway
are complicated and not fully understood [67]. In addition,
theclinicalapplicationsofhumanESCsarelimitedbyethical
concerns, as well as the potential for teratoma formation.
In addition to the ESCs produced from embryos, mes-
enchymal stromal cells (MSCs) and iPSCs with fewer limita-
tions or restrictions in ethical concerns in the research and
clinical settings have become ideal cell types for regeneration
therapies. Previous reports have demonstrated that MSCs
can be diﬀerentiated into islet-like cell clusters, and these
cell clusters can reverse the diabetic status after transplant
into streptozotocin- (STZ-) induced diabetic recipients [68].
Moreover, MSCs themselves also have strong cytoprotec-
tive eﬀects and immunosuppressive functions [69]. Several
lines of evidence have demonstrated that cotransplantation
of islets and MSCs produces superior outcomes to islet
transplantation alone. In cotransplantation therapy, MSCs
act as feeder cells that promote islet revascularization6 International Journal of Endocrinology
[70] and improve graft function [71]. Besides, MSCs also
express immunoregulatory molecules, which might help to
reestablish peripheral tolerance in diabetic recipients and to
prevent allorejection [72].
Recently, iPSCs generated from reprogrammed somatic
c e l l sh a v eb e c o m ea ne x c i t i n ga l t e r n a t i v es o u r c eo fc e l l sw i t h
pluripotent characteristicssimilartoESCs [73].Thisconcept
has been tested further using human skin ﬁbroblasts [74]
or cells from skin biopsies from patients with T1D [75]
to generate iPSC-derived islet-like clusters. These cells can
secrete C-peptide and respond to high concentrations of
glucose, suggesting that functional β cells might eventually
be generated from iPSCs. In further studies, transplantation
of iPSC-derived pancreatic beta-like cells reversed hyper-
glycemia in diabetic mouse models [76]. These data provide
an initial proof of principle for the potential clinical appli-
cation of iPSCs. Besides, if iPSCs could be generated from
patients with diabetes, they would have the same genotype
as the recipient, avoiding the problem of immune rejection.
Thus, iPSCs show promise for patient-speciﬁc regenerative
therapy. Unexpectedly and surprisingly, autologous iPSCs
reprogrammed from fetal ﬁbroblasts by viral or nonviral
geneticapproacheselicitT-cell-dependentimmunereactions
in genetically identical mice, resulting in their rejection [77].
This is likely because of the abnormal expression of antigens
in the iPSCs, leading to a breakdown of peripheral tolerance.
Besides,therecouldbe otherunknownepigeneticdiﬀerences
between iPSCs and ESCs [78].
7. Conclusion
T1D is among the most amenable diseases for treatment
with cell replacement therapy. Clinical trials of islet trans-
plantation are showing remarkable success since the Edmon-
ton protocol was developed [79], and this glucocorticoid-
free immunosuppressive protocol was replicated successfully
[80]. However, the long-term success of this procedure is
limited by the eﬀects of allograft rejection and recurrent
autoimmunity. Moreover, the scarcity of organ donors also
frustratesthetreatmentofT1D.Toovercometheseproblems,
researchers have developed many strategies to modulate the
detrimental immune responses and have also explored the
alternative sources of insulin-secreting cells. Gene therapy
oﬀers a powerful tool to engineer islet grafts to become
resistant to inﬂammation-induced apoptosis, as well as
modifying islets to produce immunosuppressive molecules
to attenuate T-cell response. The use of stem cells in the
generation of renewable and functional β cells is now a
promising reality. Moreover, based on current knowledge
about genomic cell reprogramming, it should be possible to
developpatient-speciﬁc,autologouscellreplacementtherapy
by using iPSC-derived pancreatic β-like cells.
Although these proofs of concepts for potential pre-
clinical applications show a big breakthrough in this ﬁeld,
some issues need to be considered: (1) the duration and
expression levels of targeted genes in islets, (2) the use of
viral vectors for direct gene therapy raises the possibility of
insertional mutagenesis (retroviruses and lentiviruses) and
host immunogenicity (adenoviruses), and (3) the eﬃciency
of diﬀerentiation of insulin-secreting cells from stem cells.
In conclusion, further investigations are required to
develop the most potent graft-speciﬁc immunoregulatory
therapies and to generate safe and stable sources of insulin-
secreting cells for clinical islet transplantation or cell replace-
ment treatments.
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